Health-care companies rose as weak economic data spurred demand for defensive stocks.
Merck shares recouped some of their recent losses after the Big Pharma company struck a deal with Finnish peer Orion to convert a 2022 co-development and co-commercialization agreement into an exclusive Merck license for a certain cancer drug.
Teva Pharmaceuticals Industries slipped after a report said the Federal Trade Commission has opened an investigation into the Israeli generics company, citing its refusal to take down roughly two dozen patents for its asthma and COPD inhalers.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
07-01-24 1728ET
